| Recruiting | Immunogenicity and Safety PCV-20 of the Vaccine Administered During an Acute Febrile Illness in Adults NCT06822907 | Centre Hospitalier Universitaire de Saint Etienne | Phase 4 |
| Recruiting | A Study to Evaluate the Immunogenicity and Safety of 13-valent Pneumococcal Conjugate Vaccine (PCV13i) in Heal NCT07017777 | CanSino Biologics Inc. | Phase 3 |
| Active Not Recruiting | Study of the Safety and Immunogenicity of Catch-up Vaccination With a 21-valent Pneumococcal Conjugate Vaccine NCT06838000 | Sanofi Pasteur, a Sanofi Company | Phase 3 |
| Not Yet Recruiting | The Effect of AUDIT and Feedback on Pneumococcal Vaccination Coverage NCT05920499 | Bert Vaes | N/A |
| Recruiting | In-depth Analysis of the Immune Responses in the Upper Respiratory Tract in Older Adults Infected or Colonized NCT06998251 | University Hospital, Geneva | — |
| Recruiting | A Phase 3 Study to Evaluate the Immunogenicity and Safety of Minhai's PCV13-DT/TT Vaccine As Compared to Pfize NCT06608199 | Beijing Minhai Biotechnology Co., Ltd | Phase 3 |
| Completed | Extension Safety and Immunogenicity Study of GPNV-001 NCT05982314 | GPN Vaccines | Phase 1 / Phase 2 |
| Unknown | Concomitant Administration of the Novavax Vaccine and a 20-valent Pneumococcal Conjugate Vaccine in Adults Age NCT05767606 | Medical University of Vienna | Phase 4 |
| Completed | Lot-to-lot Consistency of 23-valent Pneumococcal Polysaccharide Vaccine NCT05731115 | Sinovac Biotech Co., Ltd | Phase 4 |
| Completed | Safety, Tolerability and Immunogenicity of an Inactivated Whole-cell Pneumococcal Vaccine Gamma-PN3. NCT05667740 | GPN Vaccines | Phase 1 |
| Completed | Safety and Immunogenicity Study of a 13-valent Pneumococcal Polysaccharide Conjugate Vaccine NCT05092386 | Sinovac Life Sciences Co., Ltd. | Phase 1 |
| Active Not Recruiting | Evaluating the Effectiveness of a Pneumococcal Immunisation Campaign in a Camp for Internally Displaced People NCT04945681 | London School of Hygiene and Tropical Medicine | Phase 4 |
| Unknown | Phase I Clinical Trial of a Candidate PCV13 in Healthy People NCT05602480 | Wuhan BravoVax Co., Ltd. | Phase 1 |
| Completed | Immunogenicity and Safety of 23-valent Pneumococcal Polysaccharide Vaccine NCT05477693 | Sinovac Biotech Co., Ltd | Phase 4 |
| Completed | A Phase 2 Study to Evaluate the Safety, Tolerability, and Immune Response of AFX3772 Vaccine in Healthy Infant NCT05412030 | GlaxoSmithKline | Phase 2 |
| Completed | Serotype Distribution in Hospitalized Adult With Pneumococcal Community Acquired Pneumonia in France NCT05380193 | Institut National de la Santé Et de la Recherche Médicale, France | — |
| Completed | A Clinical Trial of 23-valent Pneumococcal Polysaccharide Vaccine NCT04989465 | Sinovac Biotech Co., Ltd | Phase 4 |
| Unknown | Immunogenicity After Revaccination With 23-valent Pneumococcal Polysaccharide Vaccine: Healthy Elderly People NCT04875858 | Korea University Guro Hospital | Phase 4 |
| Recruiting | Safety and Immunogenicity Following Meningococcal and Pneumococcal Immunization Among Adult People Living With NCT04875819 | Thomas Benfield | Phase 4 |
| Completed | Phase III Clinical Trial of a Candidate PCV13 in Healthy People Aged 6 Weeks and Above (PICTPCV13i) NCT04841369 | CanSino Biologics Inc. | Phase 3 |
| Completed | Evaluation of Prime-boost Anti-pneumococcal Vaccination in Patients With Diffuse Large B Cell Lymphoma Treated NCT04214444 | University Hospital, Tours | Phase 3 |
| Completed | Study to Evaluate the Safety, Tolerability, and Immunogenicity of V114 in Healthy Japanese Infants (V114-033) NCT04384107 | Merck Sharp & Dohme LLC | Phase 3 |
| Completed | Phase I Clinical Trial of a Candidate PCV13 in Healthy People Aged 6 Weeks and Above NCT04100772 | CanSino Biologics Inc. | Phase 1 |
| Unknown | Pneumococcal Vaccination in Patients With Chronic Lymphocytic Leukaemia NCT05145101 | Hannah Garcia Garrido | — |
| Completed | Safety and Immunogenicity of V114 in Children Infected With Human Immunodeficiency Virus (HIV) (V114-030/PNEU- NCT03921424 | Merck Sharp & Dohme LLC | Phase 3 |
| Completed | Safety, Tolerability, and Immunogenicity of V114 in Healthy Infants (V114-025) NCT04031846 | Merck Sharp & Dohme LLC | Phase 3 |
| Completed | Safety, Tolerability, and Immunogenicity of a 3-dose Regimen of V114 in Healthy Infants (PNEU-PED-EU-2/V114-02 NCT04016714 | Merck Sharp & Dohme LLC | Phase 3 |
| Completed | Impact of Pharmacist-led Educational Intervention on Pneumococcal Vaccination Rates in Cancer Patients NCT05229081 | Hacettepe University | N/A |
| Completed | Safety and Immunogenicity of Catch-up Vaccination Regimens of V114 (V114-024) NCT03885934 | Merck Sharp & Dohme LLC | Phase 3 |
| Completed | Safety, Tolerability, and Immunogenicity of V114 in Healthy Infants (V114-029) NCT03893448 | Merck Sharp & Dohme LLC | Phase 3 |
| Completed | Safety and Immunogenicity of V114 in Healthy Adults (V114-019/PNEU-AGE) NCT03950622 | Merck Sharp & Dohme LLC | Phase 3 |
| Completed | Lot-to-Lot Consistency of V114 in Healthy Adults (V114-020) NCT03950856 | Merck Sharp & Dohme LLC | Phase 3 |
| Completed | Safety, Tolerability, and Immunogenicity of V114 in Healthy Japanese Infants (V114-028) NCT03848065 | Merck Sharp & Dohme LLC | Phase 1 |
| Completed | A Study to Evaluate the Safety, Tolerability, and Immunogenicity of V114 in Children With Sickle Cell Disease NCT03731182 | Merck Sharp & Dohme LLC | Phase 3 |
| Completed | A Study to Evaluate the Safety and Tolerability of V114 and Prevnar 13™ in Healthy Infants (V114-031/PNEU-LINK NCT03692871 | Merck Sharp & Dohme LLC | Phase 3 |
| Completed | A Study to Evaluate the Interchangeability of V114 and Prevnar 13™ in Healthy Infants (V114-027/PNEU-DIRECTION NCT03620162 | Merck Sharp & Dohme LLC | Phase 3 |
| Completed | A Study to Evaluate the Safety, Tolerability, and Immunogenicity of V114 When Administered Concomitantly With NCT03615482 | Merck Sharp & Dohme LLC | Phase 3 |
| Completed | A Study to Evaluate the Safety, Tolerability, and Immunogenicity of V114 in Allogeneic Hematopoietic Stem Cell NCT03565900 | Merck Sharp & Dohme LLC | Phase 3 |
| Completed | Trial to Evaluate the Safety and Immunogenicity of Multivalent Pneumococcal Vaccines in Japanese Adults 18 to NCT03642847 | Pfizer | Phase 1 |
| Completed | A Study to Evaluate the Safety, Tolerability, and Immunogenicity of V114 Followed by PNEUMOVAX™23 in Adults at NCT03547167 | Merck Sharp & Dohme LLC | Phase 3 |
| Completed | A Safety And Immunogenicity Study Of A 13-valent Pneumococcal Conjugate Vaccine In Japanese Subjects Aged 6 To NCT03571607 | Pfizer | Phase 3 |
| Completed | A Study to Evaluate the Safety, Tolerability, and Immunogenicity of V114 Followed by PNEUMOVAX™23 in Adults In NCT03480802 | Merck Sharp & Dohme LLC | Phase 3 |
| Completed | A Study Assessing 13-valent Pneumococcal Conjugate Vaccine in Healthy Chinese Infants and Young Children NCT03574389 | Pfizer | Phase 3 |
| Completed | A Study to Evaluate the Safety, Tolerability, and Immunogenicity of V114 Followed by PNEUMOVAX™23 in Healthy A NCT03480763 | Merck Sharp & Dohme LLC | Phase 3 |
| Terminated | Study to Evaluate the Safety and Immunogenicity of a Multivalent Pneumococcal Vaccine Given With Prevnar 13 in NCT03550313 | Pfizer | Phase 2 |
| Completed | Trial to Evaluate the Safety and Immunogenicity of a Multivalent Pneumococcal Vaccine in Healthy Infants NCT03512288 | Pfizer | Phase 2 |
| Terminated | Immunization To Prevent Acute COPD Exacerbations NCT03276754 | Pfizer | — |
| Completed | Sequential Versus Simultaneous Pneumococcal Vaccination in Elderly: Immunological Memory and Antibody Levels NCT02637583 | Jena University Hospital | Phase 4 |
| Completed | A Trial To Evaluate A Multivalent Pneumococcal Conjugate Vaccine In Healthy Adults 50-85 Years Of Age NCT03313050 | Pfizer | Phase 2 |
| Completed | Trial to Evaluate the Safety and Immunogenicity of a Multivalent Pneumococcal Conjugate Vaccine in Adults 60 T NCT03313037 | Pfizer | Phase 2 |
| Completed | A Study to Evaluate the Safety, Tolerability, and Immunogenicity of Two Lots of V114 in Healthy Infants (V114- NCT02987972 | Merck Sharp & Dohme LLC | Phase 2 |
| Completed | A Phase 1, Randomized, Controlled, Observer-blinded Trial to Evaluate the Safety and Immunogenicity of a Multi NCT02955160 | Pfizer | Phase 1 |
| Completed | A Phase I Clinical Trial of a 13-valent Pneumococcal Conjugate Vaccine and 14-valent Pneumococcal Conjugate Va NCT02892812 | LG Life Sciences | Phase 1 |
| Completed | PCV13 in Non-pregnant Papua New Guinean Women NCT04183322 | Telethon Kids Institute | — |
| Completed | Safety, Tolerability, Efficacy and Pharmacodynamics of CAL02 in Severe Pneumonia Caused by Streptococcus Pneum NCT02583373 | Combioxin SA | Phase 1 |
| Completed | Immunogenicity and Safety Study of NBP606 in Healthy Toddlers NCT02927444 | SK Chemicals Co., Ltd. | Phase 3 |
| Completed | An Incitative Multifaceted PROcedure for Pneumococcal Vaccination at the Emergency Department NCT01899365 | Centre Hospitalier Princesse Grace | — |
| Completed | Enhancing a Sustainable Pharmacy-based Immunization Program in Two States NCT02615470 | Auburn University | N/A |
| Completed | Safety, Tolerability, and Immunogenicity of V114 Compared to Prevnar 13™ in PPSV23-vaccinated Healthy Adults ≥ NCT02573181 | Merck Sharp & Dohme LLC | Phase 2 |
| Completed | Safety, Tolerability, and Immunogenicity of Two Formulations of V114 in Healthy Adults 50 Years of Age or Olde NCT02547649 | Merck Sharp & Dohme LLC | Phase 2 |
| Completed | A Study to Evaluate the Safety, Tolerability and Immunogenicity of V114 in Healthy Adults and Infants (V114-00 NCT02531373 | Merck Sharp & Dohme LLC | Phase 1 / Phase 2 |
| Completed | Safety and Immunogenicity Study of 23-valent Pneumococcal Polysaccharide Vaccine in Healthy Children, Adults a NCT02451969 | Sinovac Biotech Co., Ltd | Phase 3 |
| Terminated | Systematic Search for Primary Immunodeficiency in Adults With Infections NCT02972281 | University Hospital, Lille | N/A |
| Withdrawn | Antibodies and Memory Cells Role After Different Pneumococcal Vaccines in HIV Adults NCT02357823 | University of Siena | — |
| Completed | Immunogenicity and Safety Study of NBP606 in Healthy Infants NCT02201030 | SK Chemicals Co., Ltd. | Phase 3 |
| Completed | Safety, Tolerability, and Efficacy Study of Prophylactic S. Pneumoniae Vaccine Following Challenge With S. Pne NCT02116998 | Genocea Biosciences, Inc. | Phase 2 |
| Completed | Evaluation of the Safety and Immunogenicity of Sequential Administration of Prevnar 13™ and Pneumovax™ 23 in H NCT02225587 | Merck Sharp & Dohme LLC | Phase 3 |
| Unknown | Mechanisms of Impaired HIV-associated B Cell and Pneumococcal Vaccine Responses NCT02012309 | University of Colorado, Denver | N/A |
| Unknown | Surveillance of Invasive Pneumococcal Infections in Adults (Excluding Meningitis) NCT03983616 | University Hospital, Limoges | — |
| Completed | Safety, Tolerability and Immunogenicity of V114 in Healthy Adults and Infants (V114-004) NCT02037984 | Merck Sharp & Dohme LLC | Phase 1 / Phase 2 |
| Completed | Study Immunogenicity and Safety of 13-valent Pneumococcal Conjugate Vaccine NCT02079207 | SK Chemicals Co., Ltd. | Phase 3 |
| Completed | Immunogenicity and Safety of a Tetanus-diphtheria Vaccine and a 13-valent Pneumococcal Conjugate Vaccine NCT03552445 | Korea University Guro Hospital | Phase 4 |
| Completed | MF59-adjuvanted Influenza Vaccine and 23-valent Pneumococcal Polysaccharide Vaccine NCT02225327 | Korea University Guro Hospital | Phase 4 |
| Completed | Immunogenicity and Reactogenicity of PCV13 Among Infants and Children in Burkina Faso NCT01577771 | Agence de Médecine Préventive, France | Phase 4 |
| Completed | Influenza Vaccine and Pneumococcal Vaccine NCT02582047 | Korea University Guro Hospital | Phase 4 |
| Completed | Clinical and Immunological Efficiency of Bacterial Vaccines at Adult Patients With Bronchopulmonary Pathology NCT02787863 | Mikhael Petrovich Kostinov | Phase 4 |
| Completed | The Safety, Tolerability, and Immunogenicity Profiles of a Single Dose of V114, PNEUMOVAX® 23, or PREVNAR 13® NCT01513551 | Merck Sharp & Dohme LLC | Phase 2 |
| Completed | Serological Response to Antipneumococcal Vaccination and Impact on Streptococcus Pneumoniae Nasal Carriage in NCT02123433 | University of Siena | Phase 3 |
| Completed | Study of Investigational Pneumococcal Vaccine in Healthy Adults, Toddlers and Infants NCT01446926 | Sanofi Pasteur, a Sanofi Company | Phase 1 |
| Completed | 13-valent Pneumococcal Conjugate Vaccine Study in Adults => 50 Years of Age in Mexico NCT01432262 | Pfizer | Phase 3 |
| Completed | Indirect Effects of Pneumococcal Vaccine on Nasopharyngeal Carriage NCT01311024 | Arto Palmu | — |
| Recruiting | Invasive Pneumococcal Disease Study NCT04664556 | Association Clinique Thérapeutique Infantile du val de Marne | — |
| Completed | A Study of Pneumococcal Conjugate Vaccine (V114) Compared to a Marketed Vaccine (V114-003) NCT01215188 | Merck Sharp & Dohme LLC | Phase 2 |
| Completed | A Study To Assess The Safety And Effectiveness Of Prevenar In Chinese Children Who Have Not Previously Receive NCT01193582 | Pfizer | Phase 4 |
| Completed | Study of an Investigational Pneumococcal Vaccine at Three Dose Levels in Healthy Adults NCT01444352 | Sanofi Pasteur, a Sanofi Company | Phase 1 |
| Completed | Safety and Immunogenicity of 13-Valent Pneumococcal Conjugate Vaccine (13vPnC) in HIV-Infected Subjects 6 Year NCT00962780 | Pfizer | Phase 3 |
| Completed | Study of Two Investigational Pneumococcal Vaccines in Healthy Adults NCT01444339 | Sanofi | Phase 1 |
| Completed | Immunity to Serotype 19A Streptococcus Pneumoniae in Children Vaccinated With PCV10 NCT04912297 | Finnish Institute for Health and Welfare | — |
| Completed | Safety & Immunogenicity of 13vPnC in HIV-Infected Subjects Aged 18 or Older Who Were Previously Immunized With NCT00963235 | Pfizer | Phase 3 |
| Completed | Safety and Tolerability Study for the Pneumococcal Conjugate Vaccine V114 Versus Prevnar™ (V114-001) NCT01215175 | Merck Sharp & Dohme LLC | Phase 1 |
| Completed | Open-Label Study Assessing The Safety, Immunogenicity and Dose Response of IC47 NCT00873431 | Valneva Austria GmbH | Phase 1 |
| Completed | Study Evaluating the Effiacy of a 13-Valent Pneumococcal Conjugate Vaccine (13vPnC) in Adults NCT00744263 | Pfizer | Phase 4 |
| Completed | Study Evaluating Safety of 13-Valent Pneumococcal Conjugate Vaccine in Healthy Elderly Subjects NCT00500266 | Pfizer | Phase 3 |
| Completed | Study to Evaluate the Immune Response of United Kingdom (UK) Infants Receiving DTaP/Hib/IPV, Meningococcal C C NCT00625677 | Public Health England | Phase 4 |
| Completed | Study Evaluating the Impact of a 13-valent Pneumococcal Conjugate Vaccine on Nasopharyngeal Colonization NCT00508742 | Pfizer | Phase 3 |
| Completed | Study Evaluating The Safety, Tolerability And Immunogenicity Of A 13-Valent Pneumococcal Conjugate Vaccine (13 NCT00546572 | Wyeth is now a wholly owned subsidiary of Pfizer | Phase 3 |
| Completed | Study Evaluating Safety and Immunogenicity of 13-Valent Pneumococcal Conjugate Vaccine With Influenza Vaccine NCT00492557 | Pfizer | Phase 3 |
| Completed | Study Evaluating 13-valent Pneumococcal Conjugate Vaccine Catch-Up Regimens in Older Infants and Children NCT00452452 | Wyeth is now a wholly owned subsidiary of Pfizer | Phase 3 |
| Completed | Study Evaluating 13-valent Pneumococcal Conjugate Vaccine in Healthy Infants in India NCT00452790 | Wyeth is now a wholly owned subsidiary of Pfizer | Phase 3 |
| Completed | Pneumococcal Reference Standard NCT00479323 | National Institute of Allergy and Infectious Diseases (NIAID) | Phase 1 |
| Completed | Study Comparing a 13-valent Pneumococcal Conjugate Vaccine With 23-valent Pneumococcal Polysaccharide Vaccine NCT00427895 | Pfizer | Phase 3 |
| Completed | Study of an Investigational Pneumococcal Vaccine in Healthy Adult Volunteers NCT01444001 | Sanofi | Phase 1 |
| Completed | Study Evaluating Streptococcus Pneumoniae Nasopharyngeal Carriage Rate in Children Receiving Prevnar® NCT00488371 | Wyeth is now a wholly owned subsidiary of Pfizer | — |
| Completed | Safety and Local Tolerability of Prevenar in Indian Children NCT00488800 | Wyeth is now a wholly owned subsidiary of Pfizer | — |
| Completed | PneuMum: Pneumococcal Vaccination of Australian Indigenous Mothers NCT00714064 | Menzies School of Health Research | Phase 3 |
| Unknown | PneuMum: Pneumococcal Vaccination of Australian Indigenous Mothers to See if it Protects Their Babies From Ear NCT00310349 | University of Melbourne | Phase 3 |
| Completed | Long-term Impact of Pneumococcal Conjugate Vaccine on Carriage NCT00294021 | Johns Hopkins Bloomberg School of Public Health | — |
| Completed | Pneumococcal Vaccination of Fiji Infants NCT00170612 | University of Melbourne | Phase 2 |
| Completed | Study Evaluating 7-Valent Pneumococcal Conjugate Vaccine in Healthy Infants NCT00488826 | Wyeth is now a wholly owned subsidiary of Pfizer | Phase 1 |
| Completed | Study of Streptococcus Pneumoniae in Nose and Throats of Infants With Acute Otitis Media NCT00195611 | Wyeth is now a wholly owned subsidiary of Pfizer | — |
| Unknown | Safety of and Immune Response to a Pneumococcal Vaccine (PncCV) in HIV Infected and Uninfected Children NCT00099658 | CIPRA SA | N/A |
| Completed | Response of United Kingdom (UK) Infants to a Reduced Primary Schedule With Meningococcal C and Pneumococcal Co NCT00197808 | Public Health England | Phase 4 |
| Completed | A Study of V110 a Pneumococcal Vaccine in Healthy Adults (V110-013) NCT00127153 | Merck Sharp & Dohme LLC | Phase 3 |
| Completed | Study Evaluating Prevenar Vaccine in Healthy Infants NCT00276107 | Wyeth is now a wholly owned subsidiary of Pfizer | Phase 4 |
| Completed | Early Versus Delayed Pneumococcal Vaccination in HIV NCT00137605 | CIHR Canadian HIV Trials Network | Phase 1 / Phase 2 |
| Completed | Study Evaluating Pneumococcal Vaccine in Healthy Infants NCT00205803 | Wyeth is now a wholly owned subsidiary of Pfizer | Phase 1 / Phase 2 |
| Completed | Mother's Gift Project NCT00142389 | Johns Hopkins Bloomberg School of Public Health | Phase 1 / Phase 2 |
| Completed | Study Investigating Administration of Prevenar for Post-Marketing Surveillance NCT00195390 | Wyeth is now a wholly owned subsidiary of Pfizer | — |
| Completed | Immunogenicity of PCV-7 Vaccine in VLBW Infants NCT00273325 | NICHD Neonatal Research Network | — |
| Completed | Pneumococcal Conjugate Vaccine With Pneumococcal Polysaccharide Vaccine and Tetanus/Diphtheria Vaccine NCT00164411 | Centers for Disease Control and Prevention | Phase 1 |
| Completed | Humoral Determinants of Immunity to Pneumococcal Infection NCT00304382 | VA Office of Research and Development | Phase 4 |
| Completed | Immunogenicity and Reactogenicity of Pneumococcal Polysaccharide and Conjugate Vaccines in Native Elders NCT00153543 | Centers for Disease Control and Prevention | Phase 1 |
| Terminated | Immunogenicity and Safety Study of Pneumococcal 7-Valent Conjugate Vaccine in Sickle Cell Disease Infants. NCT00368186 | Wyeth is now a wholly owned subsidiary of Pfizer | Phase 4 |
| Completed | Efficacy Trial of Two Pneumococcal Conjugate Vaccines (PncCRM and PncOMPC) for Prevention of Acute Otitis Medi NCT00378417 | Finnish Institute for Health and Welfare | Phase 3 |
| Completed | Pneumococcal Vaccine and Routine Pediatric Immunizations in HIV-Infected Children Receiving Anti-HIV Drugs NCT00013871 | National Institute of Allergy and Infectious Diseases (NIAID) | N/A |
| Withdrawn | Evaluating the Safety and Immune Response to Two Pneumococcal Vaccines in HIV-Infected Pregnant Women NCT01443117 | National Institute of Allergy and Infectious Diseases (NIAID) | Phase 2 |
| Completed | Effects of MAC Preventive Therapy on Disease-Causing Bacteria in HIV-Infected Patients: A Substudy of CPCRA 04 NCT00000933 | National Institute of Allergy and Infectious Diseases (NIAID) | — |
| Completed | A Double-Blind Placebo-Controlled Trial of the Safety and Immunogenicity of a Seven Valent Pneumococcal Conjug NCT00000829 | National Institute of Allergy and Infectious Diseases (NIAID) | Phase 1 |